BB Biotech AG
BION
Rank in Stocks
#4507
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG.... BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
Share Price
$61.40
Last synced: 2026-10-21
Market Cap
$3.39B
Change (1 day)
-5.95%
Change (1 year)
25.48%
Country
CH
Trade BB Biotech AG (BION)
Category
Financial Services
P/E ratio for BB Biotech AG (BION)
P/E ratio as of 2026 TTM: 0
According to BB Biotech AG latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for BB Biotech AG from 2026 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 24.09 | - |
US
|
|
| - | - |
SE
|
|
| 23.60 | - |
US
|
|
| 25.48 | - |
US
|
|
| 26.01 | - |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.